Dual PTEN / p53 mRNA-Loaded Lipid Nanoparticles for Tumor Suppressor Restoration and Enhanced Antitumor Activity in PTEN-Null and TP53 Mutant Prostate Cancer
Year: 2026
Type: article
Abstract: Messenger RNA (mRNA)-based therapeutics have emerged as a promising strategy for restoring disease-associated protein function without the risk of genomic integration. Although lipid nanoparticles (LNPs) enable efficient intracellular delivery of therapeutic mRNAs, most anticancer studies have focused on the restoration of a single tumor suppressor, which may be insufficient for tumors harboring concurrent deficiencies in multiple tumor suppressor pathways. Here, we developed a dual mRNA-loaded protopanaxadiol-derived lipid nanoparticle (PPD-LNP) platform coencapsulating PTEN and p53 mRNAs (PTEN/p53m-LNPs) to simultaneously restore two complementary tumor suppressor functions in PTEN/TP53-deficient PC-3 prostate cancer cells. Both therapeutic mRNAs were designed using the same proprietary 5′ and 3′ untranslated region (UTR) architecture to provide a common mRNA expression framework for PTEN and p53. Treatment with PTEN/p53m-LNPs restored both PTEN and p53 protein expression and markedly reduced phosphorylated AKT (Ser473), consistent with suppression of PI3K/AKT signaling. Furthermore, p53 restoration was accompanied by increased expression of the canonical p53 downstream targets p21 and MDM2, providing molecular evidence of functional p53 activity. Compared with either single-mRNA formulation, dual mRNA delivery produced greater inhibition of cell viability, reduced clonogenic colony formation by approximately 89%, and significantly suppressed cell migration and invasion. These findings demonstrate that codelivery of dual therapeutic mRNAs using a single PPD-LNP enables simultaneous restoration of complementary tumor suppressor functions and enhanced antitumor activity. This study provides a proof-of-concept for multi-mRNA tumor suppressor restoration in cancer cells with concurrent tumor suppressor deficiencies.
Source: ACS Bio & Med Chem Au
Institution: Yonsei University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,500
OpenAlex ID: W7233895634
